Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26217998 | 0.88 | MEN1 (0.46) | MEN1KMT2AGRIN1GRIN2AGRIN2D | |
| SCHEMBL2433970 | 0.83 | POLB (0.57) | MEN1KMT2APOLBALDH1A1TSHR | |
| SCHEMBL7588383 | 0.83 | POLB (0.64) | MEN1KMT2APOLBALDH1A1TSHR | |
| SCHEMBL4451716 | 0.83 | MEN1 (0.56) | MEN1KMT2AGRIN1GRIN2AGRIN2D | |
| SCHEMBL503339 | 0.83 | POLB (0.64) | MEN1KMT2APOLBALDH1A1TSHR | |
| SCHEMBL4151999 | 0.83 | MEN1 (0.52) | MEN1KMT2AGRIN1GRIN2AGRIN2D | |
| SCHEMBL4579249 | 0.82 | MEN1 (0.47) | MEN1KMT2AGRIN1GRIN2AGRIN2D | |
| Hydrochloric Acid SCHEMBL10532450 | 0.81 | POLB (0.62) | MEN1KMT2APOLBALDH1A1TSHR | |
| SCHEMBL6159632 | 0.81 | GRIN1 (0.58) | MEN1KMT2AGRIN1GRIN2AGRIN2D | |
| SCHEMBL21747117 | 0.80 | MEN1 (0.49) | MEN1KMT2AGRIN1GRIN2AGRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129033-A1 | METAP2 INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-04-24 | — | — | US | disclosed |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250000797-A1 | NANOMATERIALS | GUIDE THERAPEUTICS, LLC | 2025-01-02 | — | — | US | disclosed |
| EP-4479133-A1 | METAP2 INHIBITORS AND USES THEREOF | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) | 2024-12-25 | — | — | EP | disclosed |
| CN-118871428-A | METAP2 inhibitors and uses thereof | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-111432810-B | Aminoadamantane nitrate compounds and their use for treating CNS disorders | 潘诺拉马研究公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| WO-2023156996-A1 | METAP2 INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-08-24 | — | — | WO | disclosed |
| US-20230130425-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | PANORAMA RESEARCH, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20030130354-A1 | 1-(Adamantyl) amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | VERNALIS RESEARCH LIMITED | 2003-07-10 | — | — | US | disclosed |
| EP-1272176-A1 | ADAMANTYL DERIVATIVES AS ANTI-CANCER AGENTS | Galderma Research & Development, S.N.C. (FR) | 2003-01-08 | — | — | EP | disclosed |
| US-6500866-B1 | PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS BY ADMINISTERING N-METHYL-D-ASPARTATE RECEPTOR ANTAGONIST OR PRODRUGS SUCH AS 3,5-DIMETHYL-1-ADAMANTANECARBOXIMIDAMIDE HYDROCHLORIDE | VERNALIS RESEARCH LIMITED (GB) | 2002-12-31 | — | — | US | disclosed |
| WO-2001056563-A9 | ADAMANTYL DERIVATIVES AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2002-10-31 | — | — | WO | disclosed |
| EP-1037874-B1 | 1-(ADAMANTYL)AMIDINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RES LTD (GB) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001056563-A1 | ADAMANTYL DERIVATIVES AS ANTI-CANCER AGENTS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2001-08-09 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-1037874-A1 | 1-(ADAMANTYL)AMIDINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2000-09-27 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999031051-A1 | 1-(ADAMANTYL)AMIDINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | CEREBRUS PHARMACEUTICALS LIMITED (GB) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | MEN1 2207/4885KMT2A 33/4885GRIN1 3808/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | MEN1 3338/4885KMT2A 3963/4885GRIN1 2040/4885 |
| US-20230130425-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | NLN, SLC1A2, AANAT | MEN1 1333/4885KMT2A 1928/4885GRIN1 98/4885 |
| US-20250000797-A1 | NANOMATERIALS | POLRMT, PHOSPHO1, FABP1 | MEN1 2019/4885KMT2A 2411/4885GRIN1 3471/4885 |
| US-20030130354-A1 | 1-(Adamantyl) amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | SLC1A2, GRIN1, GRM1 | MEN1 751/4885KMT2A 2627/4885GRIN1 2/4885 |
| US-20250129033-A1 | METAP2 INHIBITORS AND USES THEREOF | METAP2, METAP1, SPINT2 | MEN1 601/4885KMT2A 2825/4885GRIN1 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.